The clinical responses observed following treatment with immune checkpoint inhibitors
(ICIs) support immunotherapy as a potential anticancer treatment. However, a large …

Oral squamous cell carcinoma (OSCC) develops on the mucosal epithelium of the oral
cavity. It accounts for approximately 90% of oral malignancies and impairs appearance …

Myeloid-derived suppressor cells (MDSCs) are a heterogenic population of immature
myeloid cells with immunosuppressive effects, which undergo massive expansion during …

Myeloid-derived suppressor cells (MDSCs) are pathologically activated neutrophils and
monocytes with potent immunosuppressive activity. They are implicated in the regulation of …

Despite the remarkable success of immune checkpoint inhibitors (ICIs) in melanoma
treatment, resistance to them remains a substantial clinical challenge. Myeloid-derived …

The successful outcomes of chimeric antigen receptor (CAR) T-cell therapy in treating
hematologic cancers have increased the previously unprecedented excitement to use this …

Advances in immunotherapy have led to durable and long‐term benefits in a subset of
patients across a number of solid tumor types. Understanding of the subsets of patients that …

Immunotherapies have revolutionized the treatment paradigms of various types of cancers.
However, most of these immunomodulatory strategies focus on harnessing adaptive …

Chimeric antigen receptor (CAR) T cell therapies have demonstrated remarkable efficacy for
the treatment of hematological malignancies. However, in patients with solid tumors …

Anticancer agents continue to dominate the list of newly approved drugs, approximately half
of which are immunotherapies. This trend illustrates the considerable promise of cancer …